RenovoRx completes Phase III enrollment, raises 2026 revenue guidance

RenovoRx said its Phase III "TIGeR-PaC" trial has reached full enrollment. The company notified trial investigators on August 7, 2026 that enrollment is closing, with trial completion expected in the first half of 2027 once 86 patient deaths, the trial's measured events, have been recorded.¹ As of August 11, 2026, 78 events had occurred.¹ Topline data are expected in the second half of 2027.¹ The trial's primary endpoint is overall survival, comparing RenovoRx's targeted intra-arterial gemcitabine delivery method against standard systemic gemcitabine plus Abraxane in locally advanced pancreatic cancer.¹

The company noted that an independent Data Monitoring Committee had recommended the trial continue without modification following a second interim analysis in 2025.¹

Separately, RenovoRx disclosed that in early August 2026 a cancer center customer used RenovoCath for the first time to treat sarcoma, a use case outside locally advanced pancreatic cancer, in a case involving a physician who had previously used the device in LAPC patients.¹

On commercial metrics, quarterly revenue was $909,000, up about 61% from the first quarter of 2026 and about 115% from the second quarter of 2025.¹ The company ended the quarter with 21 active commercial cancer center customers, up more than 30% from 16 at the time of its first-quarter call.¹ RenovoRx raised its full-year 2026 revenue guidance to a range of $3.75 million to $4.25 million, from a prior range of $3.0 million to $4.0 million.¹

On cash, cash and cash equivalents were approximately $9.5 million as of June 30, 2026, down from approximately $12.4 million at March 31, 2026.¹ The company said its current cash resources are sufficient to fund operations into the second half of 2027.¹